Clinical Trial Update: Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pembrolizumab in combination with ibrutinib for advanced, refractory colorectal cancers has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Ibrutinib (ibrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Colon Cancer, Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-01-22